The Endocannabinoid System in PTSD: Molecular Targets for Modulating Fear and Anxiety

Abstract

Fear and anxiety perform essential protective roles, yet when they become dysregulated, they can trap trauma survivors in persistent hypervigilance and distress. Post-traumatic stress disorder (PTSD) manifests as intrusive memories, avoidance, and heightened arousal long after the precipitating event. Although current pharmacotherapies – including selective serotonin reuptake inhibitors, adrenergic blockers, benzodiazepines, and atypical antipsychotics – provide relief for some, many patients contend with residual symptoms or intolerable adverse effects. Recent discoveries position the endocannabinoid system as a pivotal regulator of fear acquisition, consolidation, and extinction. Clinical observations of altered anandamide levels and cannabinoid receptor CB₁ upregulation in individuals with severe PTSD underscore the therapeutic potential of restoring endocannabinoid tone. Preclinical studies demonstrate that direct CB₁ agonists, fatty acid amide hydrolase (FAAH) inhibitors, and phytocannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) can facilitate extinction learning and attenuate anxiety-like behaviours. Preliminary human trials report that nabilone alleviates trauma-related nightmares and that acute cannabinoid administration modulates amygdala reactivity to a threat. Yet optimal dosing strategies, sex-specific responses, and ideal THC:CBD ratios remain to be defined. Self-medication with cannabis can offer transient relief but carries a risk of cannabis use disorder and potential worsening of PTSD symptoms. By elucidating molecular targets – including CB₁, CB₂, FAAH, and monoacylglycerol lipase – this review outlines a strategic framework for next-generation cannabinoid-based interventions. Harnessing the endocannabinoid system promises to expand the therapeutic arsenal for PTSD, offering hope for more effective and better-tolerated treatments.

Keywords

posttraumatic stress disorder (PTSD) - stress - anxiety disorders

Publication History

Received: 28 May 2025

Accepted after revision: 06 June 2025

Article published online:
11 August 2025

• References

• 1 Maeng LY, Milad MR. Post-Traumatic Stress Disorder: The Relationship Between the Fear Response and Chronic Stress. Chronic Stress (Thousand Oaks) 2017; 1: 2470547017713297
• 2 Pitman RK, Rasmusson AM, Koenen KC. et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci 2012; 13: 769-787
• 3 Marsicano G, Wotjak CT, Azad SC. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-534
• 4 Steenkamp MM, Litz BT, Hoge CW. et al. Psychotherapy for military-related PTSD: A review of randomized clinical trials. JAMA 2015; 314: 489-500
• 5 Neumeister A. The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD. Depress Anxiety 2013; 30: 93-96
• 6 Chhatwal JP, Ressler KJ. Modulation of fear and anxiety by the endogenous cannabinoid system. CNS Spectr 2007; 12: 211-220
• 7 Hill MN, Bierer LM, Makotkine I. et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 2013; 38: 2952-2961
• 8 Hauer D, Schelling G, Gola H. et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS ONE 2013; 8: e62741
• 9 Wilker S, Pfeiffer A, Elbert T. et al. Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 2016; 67: 198-206
• 10 Botsford C, Brellenthin AG, Cisler JM. et al. Circulating endocannabinoids and psychological outcomes in women with PTSD. J Anxiety Disord 2023; 93: 102656
• 11 Papini S, Sullivan GM, Hien DA. et al. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: A critical review of preclinical research. Biol Psychol 2015; 104: 8-18
• 12 LaFrance EM, Glodosky NC, Bonn-Miller M. et al. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord 2020; 274: 298-304
• 13 Bonn-Miller MO, Boden MT, Bucossi MM. et al. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users with PTSD. Am J Drug Alcohol Abuse 2014; 40: 23-30
• 14 Rodas JD, George TP, Hassan AN. A systematic review of the clinical effects of cannabis and cannabinoids in posttraumatic stress disorder symptoms and symptom clusters. J Clin Psychiatry 2024; 85: 23r14862
• 15 Ruehle S, Rey AA, Remmers F. et al. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 2012; 26: 23-39
• 16 Evanson NK, Tasker JG, Hill MN. et al. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signalling. Endocrinology 2010; 151: 4811-4819
• 17 Gowatch LC, Evanski JM, Ely SL. et al. Endocannabinoids and Stress-Related Neuropsychiatric Disorders: A Systematic Review and Meta-Analysis of Basal Concentrations and Response to Acute Psychosocial Stress. Cannabis Cannabinoid Res 2024; 9: 1217-1234
• 18 Neumeister A, Normandin MD, Pietrzak RH. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 2013; 18: 1034-1040
• 19 Dincheva I, Drysdale AT, Hartley CA. et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun 2015; 6: 6395
• 20 McPartland JM, Duncan M, Di Marzo V. et al. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 2015; 172: 737-753
• 21 Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163: 1344-1364
• 22 Karniol IG, Shirakawa I, Kasinski N. et al. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol 1974; 28: 172-177
• 23 Madras BK. Tinkering with THC-to-CBD ratios in Marijuana. Neuropsychopharmacology 2019; 44: 215-216
• 24 Phan KL, Angstadt M, Golden J. et al. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008; 28: 2313-2319
• 25 El Batsh MM, Assareh N, Marsden CA. et al. Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl.) 2012; 221: 239-247
• 26 Stern CA, Gazarini L, Takahashi RN. et al. On disruption of fear memory by reconsolidation blockade: Evidence from cannabidiol treatment. Neuropsychopharmacology 2012; 37: 2132-2142
• 27 Guimarães FS, Chiaretti TM, Graeff FG. et al. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl.) 1990; 100: 558-559
• 28 Hill MN, Patel S, Carrier EJ. et al. Downregulation of endocannabinoid signalling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-515
• 29 Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012; 204: 207-229
• 30 Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81: 331-342
• 31 Zuardi AW, Shirakawa I, Finkelfarb E. et al. Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology (Berl.) 1982; 76: 245-250
• 32 Bergamaschi MM, Queiroz RH, Chagas MH. et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011; 36: 1219-1226
• 33 Bonn-Miller MO, Sisley S, Riggs P. et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomised cross-over clinical trial. PLoS ONE 2021; 16: e0246990
• 34 Jetly R, Heber A, Fraser G. et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 2015; 51: 585-588
• 35 Rabinak CA, Blanchette A, Zabik NL. et al. Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: A preliminary study. Psychopharmacology (Berl.) 2020; 237: 1813-1826
• 36 Roitman P, Mechoulam R, Cooper-Kazaz R. et al. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 2014; 34: 587-591
• 37 Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs 2014; 46: 73-77
• 38 Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry 2015; 76: 1174-1180
• 39 Han K, Wang JY, Wang PY. et al. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res 2024; 339: 116049
• 40 Coelho CF, Vieira RP, Araújo-Junior OS. et al. The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials. Life (Basel) 2024; 14: 1373
• 41 Gundugurti PR, Banda N, Yadlapalli SSR. et al. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. Asian J Psychiatr 2024; 97: 104073
• 42 Das RK, Kamboj SK, Ramadas M. et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl.) 2013; 226: 781-792
• 43 Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009; 15: 84-88
• 44 Gunduz-Cinar O, Hill MN, McEwen BS. et al. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 2013; 34: 637-644
• 45 Gunduz-Cinar O, MacPherson KP, Cinar R. et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013; 18: 813-823
• 46 Chhatwal JP, Davis M, Maguschak KA. et al. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005; 30: 516-524
• 47 Mayo LM, Asratian A, Lindé J. et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: A randomised, controlled experimental medicine trial. Biol Psychiatry 2020; 87: 538-547
• 48 Tripathi RKP. A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents. Eur J Med Chem 2020; 188: 111953
• 49 Long JZ, Nomura DK, Cravatt BF. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 2009; 16: 744-753
• 50 Mayo LM, Rabinak CA, Hill MN. et al. Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: A promising case of preclinical-clinical translation?. Biol Psychiatry 2022; 91: 262-272
• 51 Hartley ND, Gunduz-Cinar O, Halladay L. et al. 2-arachidonoylglycerol signaling impairs short-term fear extinction. Transl Psychiatry 2016; 6: e749
• 52 Olff M. Sex and gender differences in post-traumatic stress disorder: an update. Eur J Psychotraumatol 2017; 8: 1351204
• 53 Milad MR, Igoe SA, Lebron-Milad K. et al. Estrous cycle phase and gonadal hormones influence conditioned fear extinction. Neuroscience 2009; 164: 887-895
• 54 Huang GZ, Woolley CS. Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism. Neuron 2012; 74: 801-808
• 55 Ney LJ, Matthews A, Bruno R. et al. Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder. Neurosci Biobehav Rev 2018; 94: 302-320
• 56 Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med 2022; 20: 259
• 57 MacCallum CA, de Freitas L, Lo LA. et al. Cannabinoid-Related Adverse Events and Impairment. In: Narouze, S.N. (eds) Cannabinoids and Pain. Springer; Cham: 2021
• 58 Steenkamp MM, Blessing EM, Galatzer-Levy IR. et al. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. Depress Anxiety 2017; 34: 207-216
• 59 Bajtel Á, Kiss T, Tóth B. et al. The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials. Pharmaceuticals (Basel) 2022; 15: 100
• 60 Tihăuan BM, Onisei T, Slootweg W. et al. Cannabidiol-A friend or a foe?. Eur J Pharm Sci 2025; 208: 107036
• 61 Smith RT, Gruber SA. Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions. Front Psychiatry 2023; 13: 1055481
• 62 Stack SK, Wheate NJ, Moloney NC. et al. The Effectiveness and Adverse Events of Cannabidiol and Tetrahydrocannabinol Used in the Treatment of Anxiety Disorders in a PTSD Subpopulation: An Interim Analysis of an Observational Study. J Pharm Technol 2023; 39: 172-182
• 63 Rubin-Kahana DS, Hassan AN, Sanches M. et al. Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample. Front Psychiatry 2022; 13: 836908
• 64 Hasin D, Walsh C. Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review. J Clin Med 2020; 10: 15
• 65 Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 2017; 8: 9-37
• 66 Connor JP, Stjepanović D, Budney AJ. et al. Clinical management of cannabis withdrawal. Addiction 2022; 117: 2075-2095
• 67 Zuardi AW, Rodrigues NP, Silva AL. et al. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front Pharmacol 2017; 8: 259